Welcome to our dedicated page for Fate Therapeutic news (Ticker: FATE), a resource for investors and traders seeking the latest updates and insights on Fate Therapeutic stock.
Fate Therapeutics develops induced pluripotent stem cell (iPSC)-derived cellular immunotherapies for cancer and autoimmune diseases. News about FATE centers on its off-the-shelf CAR T-cell and NK-cell product candidates, including FT819, FT836 and FT839, and on clinical or preclinical data presented at medical and cell-therapy meetings.
Recurring updates cover FT819 in systemic lupus erythematosus and other autoimmune diseases, next-generation CAR T programs for hematological malignancies and solid tumors, manufacturing and FDA CMC interactions, Regenerative Medicine Advanced Therapy designation, investor-conference participation, financial results, and Nasdaq employee inducement equity awards.
Fate Therapeutics (NASDAQ: FATE) will present clinical and preclinical data from its off-the-shelf CAR T-cell pipeline at the 2026 ASGCT Annual Meeting in Boston, May 11–15, 2026. Presentations cover FT819 SLE data without conditioning chemotherapy, an oral on dual-targeting FT839, and preclinical FT836 MICA/B tumor data.
Key sessions: FT819 poster May 12, FT836 poster May 13, and FT839 oral May 14. The programs focus on iPSC-derived, off-the-shelf CAR T approaches for autoimmune and oncology indications.
Fate Therapeutics (NASDAQ: FATE) granted 30,200 restricted stock units (RSUs) on May 1, 2026 to one newly hired non-executive employee as an inducement under its Amended and Restated Inducement Equity Plan in accordance with Nasdaq Listing Rule 5635(c)(4).
The grant was approved by the Compensation Committee. The RSUs vest over four years, with 25% vesting on each anniversary of the grant date, subject to continuous employment through each vesting date.
Fate Therapeutics (NASDAQ: FATE) will present clinical data for its off-the-shelf CAR T candidate FT819 at CCR–East 2026 (Destin, FL; Apr 30–May 3, 2026).
Presentation covers safety, efficacy, and translational results from 13 SLE patients (data cutoff Dec 23, 2025), including SLEDAI-2K −13 points at Month 6 and substantial FACIT-Fatigue improvements after a single FT819 dose with reduced conditioning.
Fate Therapeutics (NASDAQ: FATE) will present preclinical data for its next‑generation off‑the‑shelf CAR T candidate FT839 at the AACR Annual Meeting, April 17–22, 2026 in San Diego.
FT839 is described as a 13‑point edited, dual‑CAR product targeting CD19 and CD38, using Sword and Shield™ technology to evade host immune responses and potentially remove the need for conditioning chemotherapy. Poster: April 21, 2026, 9:00 a.m.–Noon PDT.
Fate Therapeutics (NASDAQ: FATE) said management will participate in five investor conferences in Q2 2026 with scheduled dates and locations listed below.
- April 14 — Needham Virtual Healthcare Conference (virtual)
- May 13 — Bank of America Healthcare Conference, Las Vegas
- May 19 — H.C. Wainwright BioConnect, New York
- June 4 — Jefferies Global Healthcare, New York
- June 10 — Goldman Sachs Global Healthcare, Miami Beach
The company said presentations or fireside chats may occur and live webcasts will be available under Events & Presentations on the company website, with archived replays accessible for 30 days.
Fate Therapeutics (NASDAQ: FATE) granted 7,260 restricted stock units (RSUs) on April 1, 2026 to one newly hired non-executive employee as an inducement under Nasdaq Listing Rule 5635(c)(4). The Compensation Committee approved the award under the companys Amended and Restated Inducement Equity Plan.
The RSUs vest over four years with 25% vesting on each anniversary, subject to continuous employment through each vesting date.
Fate Therapeutics (NASDAQ: FATE) granted restricted stock units representing 50,700 shares to three newly hired non-executive employees on March 2, 2026 as inducement awards under Nasdaq Listing Rule 5635(c)(4).
The awards vest over four years with 25% vesting on each anniversary, subject to continued employment.
Fate Therapeutics (NASDAQ: FATE) announced management will participate in the Leerink Partners 2026 Global Healthcare Conference on Monday, March 9, 2026 in Miami, Florida.
Management will join a fireside chat at 9:20 AM ET, host investor meetings, and provide a live webcast with an archived replay available for 90 days.
Fate Therapeutics (NASDAQ: FATE) reported Q4 and full-year 2025 results and clinical progress on Feb 26, 2026. The company ended 2025 with $205.1 million in cash, projects runway through year-end 2027, and recorded Q4 revenue of $1.4 million. FT819 achieved outpatient dosing across autoimmune indications (15 SLE, 4 SSc, 1 IIM treated) and showed a 3-month improvement in a systemic sclerosis patient. FT836 showed a >50% CEA reduction in a CRC patient without conditioning chemotherapy. Operating expenses declined ~30% in 2025 versus 2024.
Fate Therapeutics (NASDAQ: FATE) granted inducement awards on February 1, 2026 to a newly-hired non-executive employee under its Amended and Restated Inducement Equity Plan in accordance with Nasdaq Listing Rule 5635(c)(4).
The package includes 120,000 non-qualified stock options at an exercise price of $1.19 per share and 90,000 restricted stock units (RSUs). Options vest over four years (25% at one year, remainder monthly over 36 months); RSUs vest 25% each anniversary over four years, subject to continued employment.